维尔生物技术
VIR
9.96
-0.51
-4.87%
维尔生物技术
US · VIR
#2824 按市值排名
上市于 2019
9.96
-0.51
-4.87%
实时 - 追踪5344个代码 - 心跳于551秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了1家。
- 机构持股总比例下降了0.8个百分点。
机构持股
- 机构持股比例
- 88.48% -0.85pp
- 机构数量
- 286 -1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund48.09%
VC/PE Fund20.64%
Hedge Fund13.88%
Individual/Insider4.23%
Public Company3.32%
Private Company1.01%
Insurance Company0.80%
Government Pension Fund0.70%
Other7.30%
主要股东 截至 2026-06-30
BlackRock
12.22% · 20.68M 股
Arch Venture Partners, L.P.
7.50% · 12.69M 股
Vanguard Portfolio Management, LLC
6.79% · 11.50M 股
SB Investment Advisers (UK) Limited
6.47% · 10.95M 股
State Street Global Advisors
5.89% · 9.96M 股
GSK Equity Investments, Limited
5.05% · 8.55M 股
Vanguard Capital Management, LLC
4.27% · 7.23M 股
Point72 Asset Management, L.P.
3.35% · 5.67M 股
George Scangos
2.23% · 3.78M 股
Geode Capital Management, LLC
1.98% · 3.35M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 18次买入 · 31次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| George Scangos | Director | 2.23% |
| Vicki Sato | Independent Chairperson | 0.63% |
| Marianne De Backer | Chief Executive Officer | 0.59% |
| Robert Taylor Nelsen | Independent Director | 0.37% |
| Ann Hanly | Executive VP & Chief Technology Officer | 0.04% |
| Brent Sabatini | Senior VP, Principal Accounting Officer & Chief Accounting Officer | 0.04% |
| Robert J. More | Independent Director | 0.02% |
| Charles Sigal | Independent Director | 0.01% |
| Jeffrey Hatfield | Independent Director | 0.01% |
| Jason O'Byrne | -- | 0.01% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-16 | Jason O'Byrne | -- | Intent to Sell (Form 144) | -19,357 | $11.00 |
| 2026-09-08 | Jason O'Byrne | -- | Intent to Sell (Form 144) | -28,333 | $11.13 |
| 2026-08-24 | Jason O'Byrne | -- | Intent to Sell (Form 144) | -23,148 | $10.48 |
| 2026-08-23 | Jason O'Byrne | -- | Intent to Sell (Form 144) | -14,352 | $9.90 |
| 2026-08-20 | Jason O'Byrne | -- | Intent to Sell (Form 144) | -25,000 | $9.81 |
| 2026-08-10 | Alta Partners LP | -- | Other Acquisition | +8,000 | -- |
| 2026-08-10 | Robert J. More | Independent Director | Other Disposition | -8,000 | -- |
| 2026-06-28 | Sona Saira Ramasastry | Independent Director | Intent to Sell (Form 144) | -16,000 | $10.32 |
| 2026-06-08 | Timothy Coughlin | Director | Other Acquisition | +16,000 | -- |
| 2026-06-08 | Timothy Coughlin | Director | Other Derivative Acquisition | +16,000 | $8.51 |
| 2026-06-08 | Timothy Coughlin | Director | Initial Statement of Beneficial | 0 | -- |
| 2026-05-31 | Janet Napolitano | Independent Director | Automatic Disposition | -3,200 | $9.45 |
| 2026-05-31 | Brent Sabatini | Senior VP, Principal Accounting Officer & Chief Accounting Officer | Automatic Disposition | -379 | $9.45 |
| 2026-05-26 | Robert J. More | Independent Director | Other Acquisition | +8,000 | -- |
| 2026-05-26 | Robert J. More | Independent Director | Other Derivative Acquisition | +16,000 | $9.10 |
| 2026-05-26 | Norbert Bischofberger | Independent Director | Other Acquisition | +8,000 | -- |
| 2026-05-26 | Norbert Bischofberger | Independent Director | Other Derivative Acquisition | +16,000 | $9.10 |
| 2026-05-26 | Charles Sigal | Independent Director | Other Acquisition | +8,000 | -- |
| 2026-05-26 | Charles Sigal | Independent Director | Other Derivative Acquisition | +16,000 | $9.10 |
| 2026-05-26 | Janet Napolitano | Independent Director | Other Acquisition | +8,000 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
维尔生物技术 讨论区 0 条评论